Mesenchymal stem cells and type 1 diabetes treatment
Authors:
Pavla Boháčová; Vladimír Holáň
Authors‘ workplace:
Oddělení transplantační imunologie Ústavu experimentální medicíny AV ČR, v. v. i., Praha
Published in:
Vnitř Lék 2018; 64(7-8): 725-728
Category:
Reviews
Overview
Type 1 diabetes represents a serious disease which is caused by autoimmune destruction of insulin-producing B cells in the pancreas. Administration of exogenous insulin cannot replace sensitive and gentle regulation of blood glucose levels that is established by B cells in healthy individuals. Pancreas or islet transplantation is limited by a shortage of donor pancreas and by complications associated with transplantations. For those reasons, new approaches of treatment are being searched, the using of mesenchymal stem cells (MSCs) envisions a promising tool for cell-based therapy of type 1 diabetes. MSCs have a significant impact on the regulation of the immune system, are a potent source of various cytokines and growth factors and manifest multilineage differentiation abilities. In context of type 1 diabetes, MSCs can transdifferentiate into insulin-producing cells, support the regeneration of residual B cells by production of trophic and growth factors or participate in the suppression of the autoimmune reaction against B cells. This review is focused on perspectives and mechanisms of MSC-based therapy and its limitations.
Key words:
autoimmune reaction – differentiation – mesenchymal stem cells – type 1 diabetes
Sources
1. Mathis D, Vence L, Benoist C. Beta-cell death during progression to diabetes. Nature 2001; 414(6865): 792–798. Dostupné z DOI: .
2. Vrlikova D, Mokan M. Diabetes mellitus 1. typu a autoimunita. Vnitř Lék 2005; 51(11): 1297–1302.
3. Ezquer M, Arango-Rodriguez M, Giraud-Billoud M et al. Mesenchymal stem cell therapy in type 1 diabetes mellitus and its main complications: from experimental findings to clinical practice. J Stem Cell Res Ther 2014; 4(8): 227. Dostupné z DOI: .
4. [Health Quality Ontario]. Pancreas islet transplantation for patients with type 1 diabetes mellitus: a clinical evidence review. Ont Health Technol Assess Ser 2015; 15(16): 1–84.
5. Saudek F, Girman P, Lipar K et al. Transplantace pankreatu: současný stav a výhledy do budoucna. Vnitř Lék 2015; 61(7): 731–737.
6. Ding DC, Shyu WC, Lin SZ. Mesenchymal stem cells. Cell Transplant 2011; 20(1): 5–14. Dostupné z DOI: .
7. Friedenstein AJ, Piatetzky-Shapiro II, Petrakova KV. Osteogenesis in transplants of bone marrow cells. J Embryol Exp Morphol 1966; 16(3): 381–390.
8. Kobolak J, Dinnyes A, Memic A et al. Mesenchymal stem cells: Identification, phenotypic characterization, biological properties and potential for regenerative medicine through biomaterial micro-engineering of their niche. Methods 2016; 99: 62–68. Dostupné z DOI: .
9. Machado C de V, Telles PD, Nascimento IL. Immunological characteristics of mesenchymal stem cells. Rev Bras Hematol Hemoter 2013; 35(1): 62–67. Dostupné z DOI: .
10. Holan V, Hermankova B, Bohacova P et al. Distinct immunoregulatory mechanisms in mesenchymal stem cells: role of the cytokine environment. Stem Cell Rev 2016; 12(6): 654–663. Dostupné z DOI: .
11. Pistoia V, Raffaghello L. Mesenchymal stromal cells and autoimmunity. Int Immunol 2017; 29(2): 49–58. Dostupné z DOI: .
12. Gu W, Hong X, Potter C et al. Mesenchymal stem cells and vascular regeneration. Microcirculation 2017; 24(1): e12324. Dostupné z DOI: .
13. Koblas T, Zacharovova K, Berkova Z et al. In vivo differentiation of human umbilical cord blood-derived cells into insulin-producing beta cells. Folia Biol (Praha) 2009; 55(6): 224–232.
14. Chandra V, Swetha G, Muthyala S et al. Islet-like cell aggregates generated from human adipose tissue derived stem cells ameliorate experimental diabetes in mice. PLoS One 2011; 6(6): e20615. Dostupné z DOI: .
15. Boroujeni ZN, Aleyasin A. Insulin producing cells established using non-integrated lentiviral vector harboring PDX1 gene. World J Stem Cells 2013; 5(4): 217–228. Dostupné z DOI: .
16. King A. The use of animal models in diabetes research. Br J Pharmacol 2012; 166(3): 877–894. .
17. Gerace D, Martiniello-Wilks R, Nassif NT et al. CRISPR-targeted genome editing of mesenchymal stem cell-derived therapies for type 1 diabetes: a path to clinical success? Stem Cell Res Ther 2017; 8(1): 62. Dostupné z DOI: .
18. Hasegawa Y, Ogihara T, Yamada T et al. Bone marrow (BM) transplantation promotes beta-cell regeneration after acute injury through BM cell mobilization. Endocrinology 2007; 148(5): 2006–2015. .
19. Gao X, Song L, Shen K et al. Bone marrow mesenchymal stem cells promote the repair of islets from diabetic mice through paracrine actions. Mol Cell Endocrinol 2014; 388(1): 41–50. Dostupné z DOI: .
20. Fiorina P, Jurewicz M, Augello A et al. Immunomodulatory function of bone marrow-derived mesenchymal stem cells in experimental autoimmune type 1 diabetes. J Immunol 2009; 183(2): 993–1004. Dostupné z DOI: .
21. Madec AM, Mallone R, Afonso G et al. Mesenchymal stem cells protect NOD mice from diabetes by inducing regulatory T cells. Diabetologia 2009; 52(7): 1391–1399. Dostupné z DOI: .
22. Tolar J, Nauta AJ, Osborn MJ et al. Sarcoma derived from cultured mesenchymal stem cells. Stem Cells 2007; 25(2): 371–379. Dostupné z DOI: .
23. Vacanti V, Kong E, Suzuki G et al. Phenotypic changes of adult porcine mesenchymal stem cells induced by prolonged passaging in culture. J Cell Physiol 2005; 205(2): 194–201. Dostupné z DOI: .
24. Ra JC, Shin IS, Kim SH et al. Safety of intravenous infusion of human adipose tissue-derived mesenchymal stem cells in animals and humans. Stem Cells Dev 2011; 20(8): 1297–1308. Dostupné z DOI: .
25. Schu S, Nosov M, O‘Flynn L et al. Immunogenicity of allogeneic mesenchymal stem cells. J Cell Mol Med 2012; 16(9): 2094–2103. Dostupné z DOI: .
26. Phadnis SM, Ghaskadbi SM, Hardikar AA et al. Mesenchymal stem cells derived from bone marrow of diabetic patients portrait unique markers influenced by the diabetic microenvironment. Rev Diabet Stud 2009; 6(4): 260–270. Dostupné z DOI: .
27. Javorkova E, Trosan P, Zajicova A et al. Modulation of the early inflammatory microenvironment in the alkali-burned eye by systemically administered interferon-γ-treated mesenchymal stromal cells. Stem Cells Dev 2014; 23(20): 2490–2500. Dostupné z DOI: .
Labels
Diabetology Endocrinology Internal medicineArticle was published in
Internal Medicine
2018 Issue 7-8
Most read in this issue
- Low-carbohydrate diet in diabetes mellitus treatment
- Spironolactone in the treatment of hypertension: a neglected molecule
- Mesenchymal stem cells and type 1 diabetes treatment
- Controversies in the treatment of gout